Browse by author
Lookup NU author(s): Emeritus Professor Philip Home
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Insulin aspart has been shown, in medium-term studies, to achieve reductions in HbA1c without increasing the risk of major hypoglycaemia compared with pre-meal human insulin. The aim of the present 3-year study was to evaluate the long-term safety and efficacy of insulin aspart in people with type 1 diabetes. This was a 30-month extension of a multinational, multicentre, open-label, parallel-group study of 753 people with type 1 diabetes, originally randomly allocated to treatment with insulin aspart or unmodified human insulin before meals, with NPH insulin as basal insulin. Main outcomes measures were hypoglycaemia (major or minor), adverse events and HbA1c. As insulin aspart became commercially available in some countries before the end of the trial, analyses of HbA1c used 30-month data to maintain statistical power. The relative risk estimate of major hypoglycaemia was similar between treatment groups (relative risk [RR] 1.00 [95% CI 0.72, 1.39]). The risk of having a minor hypoglycaemic episode was higher with insulin aspart than with human soluble insulin (RR 1.24 [1.09, 1.39] p = 0.024). Insulin aspart was significantly superior to human insulin with respect to overall glycaemic control, with a baseline-adjusted HbA1c difference of -0.16 (-0.32, -0.01)% (p = 0.035). Insulin aspart was well tolerated and effective during long-term treatment. The HbA1c advantage was maintained with insulin aspart without any adverse impact on the rate of major hypoglycaemia. © 2005 Elsevier Ireland Ltd. All rights reserved.
Author(s): Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH
Publication type: Article
Publication status: Published
Journal: Diabetes Research and Clinical Practice
Print publication date: 01/02/2006
ISSN (print): 0168-8227
ISSN (electronic): 1872-8227
PubMed id: 16054266
Altmetrics provided by Altmetric